Details

Autor(en) / Beteiligte

• Gago-Veiga, Ana Beatriz
• Lopez-Alcaide, Noelia
• Quintas, Sonia
• Fernández Lázaro, Iris
• Casas-Limón, Javier
• Calle, Carlos
• Latorre, Germán
• González-García, Nuria
• Porta-Etessam, Jesús
• Rodriguez-Vico, Jaime
• Jaimes, Alex
• Gómez García, Andrea
• García-Azorín, David
• Guerrero-Peral, Ángel Luis
• Sierra, Álvaro
• Lozano Ros, Alberto
• Sánchez-Soblechero, Antonio
• Díaz-de-Teran, Javier
• Membrilla, Javier A
• Treviño, Cristina
• Gonzalez-Martinez, Alicia

Titel

Evaluation of the concomitant use of prophylactic treatments in patients with migraine under anti-calcitonin gene-related peptide therapies: The PREVENAC study

Ist Teil von

• European journal of neurology, 2024-05, Vol.31 (5), p.e16215

Ort / Verlag

England: John Wiley & Sons, Inc

Erscheinungsjahr

2024

Quelle

Wiley Blackwell Single Titles

Beschreibungen/Notizen

• Anti-calcitonin gene-related peptide (CGRP) therapies are recent preventive therapies approved for both episodic and chronic migraine. One of the measures of effectiveness is the withdrawal of other preventive treatments. The objective of this study is to quantify the impact of anti-CGRP drugs in concomitant preventive treatment in patients with migraine. This was an observational, retrospective, multicenter cohort study with patients from nine national headache units. Patients with migraine undergoing treatment for at least 6 months with anti-CGRP antibodies, who were initially associated with some preventive treatment (oral and/or onabotulinumtoxinA) were included. Demographic and clinical variables were collected, as well as variables related to headache. Differences according to withdrawal or nonwithdrawal were evaluated. A total of 408 patients were included, 86.52% women, 48.79 (SD = 1.46) years old. Preventive treatment was withdrawn in 43.87% (179/408), 20.83% partially and 23.04% totally. In 27.45% (112/408), it was maintained exclusively due to comorbidity and in 28.6% (117/408) due to partial efficacy. The most frequent time of withdrawal was between 3 and 5 months after the start of treatment. The baseline characteristics associated with nonwithdrawal were comorbidities: insomnia, hypertension and obesity, chronic migraine, and medication overuse. In the multivariate analysis, the absence of high blood pressure, a greater number of preventive treatments at the start, and a lower number of migraine days/month after anti-CGRP treatment were independently associated with withdrawal of the treatment (p < 0.05). Anti-CGRP antibodies allow the withdrawal of associated preventive treatment in a significant percentage of patients, which supports its effectiveness in real-life conditions.